OFIX Technical Analysis & Stock Price Forecast
This article provides a technical analysis of Orthofix Medical Inc (OFIX), indicating a "Strong Sell" consensus based on various technical signals. It details momentum indicators like RSI and MACD, support and resistance levels, and performance relative to moving averages, offering insights into the stock's current market sentiment and potential price movements.
Vanguard realignment lists 0% stake in Orthofix (OFIX) after reporting change
Vanguard has reported a 0% beneficial ownership stake in Orthofix Medical Inc. (OFIX) following an internal realignment that took effect on January 12, 2026. This change is based on SEC Release No. 34-39538, allowing subsidiaries to report beneficial ownership separately. The filing indicates a reporting format change due to internal restructuring rather than a trading event.
Tudor Investment Corp ET AL Purchases 158,197 Shares of Orthofix Medical Inc. $OFIX
Tudor Investment Corp ET AL significantly increased its stake in Orthofix Medical Inc. (NASDAQ:OFIX) by 268.8% in Q3, acquiring 158,197 shares to own a total of 217,044 shares valued at $3.18 million. Despite this increase in institutional ownership, Orthofix Medical is currently unprofitable, missed its latest EPS estimates, and has seen net selling by insiders including its CEO and CFO. Analysts maintain a mixed outlook with an average "Hold" rating and a target price of $17.25 for the medical device company.
Orthofix Medical Inc. (NASDAQ:OFIX) Receives Average Rating of "Hold" from Brokerages
Orthofix Medical Inc. (NASDAQ:OFIX) has received an average "Hold" rating from six brokerages, with an average 12-month price target of $17.25 despite some recent target cuts and upgrades. Recent insider selling by the CEO and CFO, totaling over $200,000, indicates a decrease in their holdings. The company also reported a quarterly EPS miss of ($0.06) against an expected $0.44, alongside a slight revenue beat.
OFIX PE Ratio & Valuation, Is OFIX Overvalued
Orthofix Medical Inc (OFIX) is currently considered undervalued, with a fair price estimated between $21.01 and $31.25 compared to its current price of $11.87. Its current forward P/S ratio of 0.69 is significantly below its five-year average. Despite this, a comparison to competitors shows OFIX's P/S ratio is above the industry average, which, given its 1.97% revenue growth, is deemed unsustainable.
(OFIX) and the Role of Price-Sensitive Allocations
An analysis of Orthofix Medical Inc. (OFIX) indicates a neutral sentiment in the near term with potential for moderated mid-term weakness, lacking clear price positioning. The report highlights elevated downside risk due to an absence of long-term support signals. Three institutional trading strategies are provided for different risk profiles, along with multi-timeframe signal analysis, showing current support and resistance levels.
OFIX SEC Filings - Orthofix Med Inc 10-K, 10-Q, 8-K Forms
This page provides access to Orthofix Medical Inc. (OFIX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider trading forms. Recent filings detail insider stock sales for tax coverage, Q3 2025 earnings showing net sales of $205.6 million, and discussions around non-GAAP financial measures. The platform also offers AI-powered summaries to help investors quickly understand key aspects of these regulatory documents.
Lucas Vitale Sells 4,269 Shares of Orthofix Medical (NASDAQ:OFIX) Stock
Lucas Vitale, an insider at Orthofix Medical, sold 4,269 shares of the company's stock on March 17th at an average price of $11.92, reducing his total holding by 2.59%. This comes as Orthofix Medical recently missed quarterly EPS estimates and reported negative profitability metrics, with the stock currently trading below its 50- and 200-day moving averages. Analysts hold a consensus "Hold" rating on OFIX with a target price of $17.25, following several downward revisions.
Orthofix (OFIX) executive logs tax-related sale, retains over 160K shares
Orthofix Medical Inc. executive Lucas Vitale, Chief People & Business Operations Officer, conducted a tax-related sale of 4,269 shares of common stock at $11.92 per share. This transaction was to satisfy tax withholding obligations from restricted stock units under a pre-approved sell-to-cover arrangement, with no discretionary action by Vitale. Following the sale, Vitale still holds 160,449 shares of Orthofix common stock, including 127,256 restricted stock units.
Orthofix Medical Inc Aktie: Analyst Upgrades Signal Growing Confidence in Bone-Filler Market Expansion
Orthofix Medical Inc. is experiencing increased investor confidence due to analyst upgrades and the rapid expansion of the global bone void fillers market, projected to reach $7.3 billion by 2035. The company's strategic partnership with MTF Biologics positions it as a key provider of regenerative orthopedic solutions, amidst rising competitive intensity and global demand. While the consensus is a "moderate buy," investors should consider execution risks, competition, and regulatory shifts.
Juniper Investment Company LLC Increases Stake in Orthofix Medical Inc. $OFIX
Juniper Investment Company LLC significantly increased its stake in Orthofix Medical Inc. (NASDAQ:OFIX) by 15.3% during the third quarter, making the medical device company its fourth-largest holding. Despite this increased institutional interest, Orthofix Medical reported a miss on EPS estimates and negative profitability metrics, with the stock currently trading near $11.70. The Street consensus remains a "Hold" with an average price target of $17.25, reflecting mixed analyst ratings.
Orthofix Medical Inc Stock (ISIN: US6875231068) Faces Margin Pressure as Spine Segment Growth Slows
Orthofix Medical Inc (OFIX) is experiencing significant margin pressure due to competitive headwinds in its spine and trauma segments, despite modest revenue growth in 2025. The company's spine segment shows slowing growth, while trauma fixation remains flat, prompting European investors to watch for management's cost-cutting measures and pivot to biologics for potential turnaround. Analysts maintain a 'Moderate Buy' rating, seeing potential upside if the company successfully executes its strategy to restore profitability and leverage its strong balance sheet.
Orthofix Medical Inc Stock (ISIN: US6875231068) Faces Margin Pressure as Spine Segment Growth Slows
Orthofix Medical Inc. is experiencing margin pressure due to competitive headwinds in its spine and trauma segments, despite modest revenue growth. The company's spine segment growth has slowed, and pricing pressures persist, impacting profitability. Management is focusing on cost-cutting measures and a pivot towards biologics to improve its financial outlook, which European investors are closely monitoring.
Orthofix Medical Inc Stock (ISIN: US6875231068) Faces Margin Pressure as Spine Segment Growth Slows
Orthofix Medical Inc (US6875231068) is experiencing margin pressure due to slower growth in its core spine and trauma segments, facing competitive pricing, procedure delays, and surgeon preference shifts. While the company is implementing cost-reduction programs and pursuing international expansion, particularly in Europe, the execution credibility of these strategies and the relentless competitive intensity in the orthopedic market remain key challenges. Investors are balancing the company's solid balance sheet and turnaround potential against near-term volatility and a modest cash generation profile.
A Glimpse Into The Expert Outlook On Orthofix Medical Through 5 Analysts
Five analysts recently reviewed Orthofix Medical (NASDAQ: OFIX), resulting in an average price target of $17.4, a 15.12% decrease from the previous average. These ratings range from bullish to indifferent, with multiple analysts lowering their price targets. Despite this, Orthofix Medical shows strong financial health with impressive revenue growth, net margin, ROE, and ROA, although its market capitalization is below the industry average.
Orthofix Medical (OFIX) director buys 5,000 common shares
Orthofix Medical Inc. director Vickie L. Capps purchased 5,000 shares of common stock in open-market transactions on March 9-10, 2026, at prices between $12.44 and $12.48 per share. Following these acquisitions, Capps directly holds 27,585 shares, which includes previously reported deferred stock units and shares from Orthofix's stock purchase plan. The filing sentiment is positive, indicating a notable insider investment in the company.
Halper Sadeh LLC Encourages Orthofix Medical Inc. Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Orthofix Medical Inc. (NASDAQ: OFIX) breached their fiduciary duties to shareholders. The firm encourages current Orthofix shareholders to contact them to discuss potential corporate governance reforms, the return of funds to the company, or other relief. Shareholder involvement can help improve a company's practices and enhance shareholder value.
Halper Sadeh LLC Encourages Orthofix Medical Inc. Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Orthofix Medical Inc. (NASDAQ: OFIX) breached their fiduciary duties to shareholders. The firm encourages long-term Orthofix shareholders to contact them to discuss legal rights and options, which may include seeking corporate governance reforms or the return of funds. They emphasize that shareholder involvement can enhance transparency and shareholder value.
OFIX Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Orthofix Medical Inc. – OFIX
The Rosen Law Firm, a global investor rights law firm, has announced an investigation into potential breaches of fiduciary duties by the directors and officers of Orthofix Medical Inc. (NASDAQ: OFIX). Investors who currently own shares of Orthofix Medical stock are encouraged to visit the firm's website or contact Phillip Kim for more information about their rights. The firm emphasizes its track record in securities class actions and shareholder derivative litigation, representing investors worldwide.
Insider Buying: Vickie Capps Acquires 5,000 Shares of Orthofix M
Vickie Capps, a Director at Orthofix Medical Inc (OFIX), purchased 5,000 shares of the company on March 10, 2026, increasing her total holdings to 27,585 shares. The stock was trading at $12.46, below its estimated GF Value of $15.15, suggesting it is modestly undervalued. This transaction occurs within a mixed insider sentiment trend for OFIX, with 8 insider buys and 16 insider sells over the past year.
Orthofix Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Orthofix Medical, Inc. – OFIX
Rosen Law Firm, a global investor rights law firm, has announced an investigation into potential breaches of fiduciary duties by the directors and officers of Orthofix Medical Inc. (NASDAQ: OFIX). The firm encourages current shareholders of Orthofix Medical to visit its website or contact them for more information regarding this investigation. Rosen Law Firm emphasizes its track record in securities class actions and shareholder derivative litigation, highlighting its experience and success in representing investors.
Orthofix Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Orthofix Medical, Inc. – OFIX
Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of Orthofix Medical Inc. (NASDAQ: OFIX). Investors who currently own shares of Orthofix Medical stock are encouraged to visit the firm's website or contact them directly for more information regarding this investigation. The Rosen Law Firm specializes in securities class action and shareholder derivative litigation and has a strong track record of recovering significant funds for investors.
FinancialContent - Orthofix Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Orthofix Medical, Inc. – OFIX
The Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of Orthofix Medical Inc. (NASDAQ: OFIX). Shareholders are encouraged to visit the firm's website or contact them directly for more information regarding this investigation. The firm specializes in securities class actions and shareholder derivative litigation, with a track record of significant recoveries for investors.
Orthofix Medical (NASDAQ:OFIX) Price Target Cut to $18.00 by Analysts at Stifel Nicolaus
Stifel Nicolaus analysts have reduced their price target for Orthofix Medical (NASDAQ:OFIX) to $18.00 from $22.00, while maintaining a "buy" rating. This adjustment comes after the company reported an earnings miss, with Q1 EPS of ($0.06) against an estimated $0.44. Despite varying analyst opinions, the consensus rating for Orthofix Medical is "Hold" with a target price of $17.25.
Orthofix (OFIX) executive sells 1,536 shares to cover RSU tax withholding
Orthofix Medical Inc. executive Patrick Fisher sold 1,536 shares of common stock on March 4 and 5, 2026, at weighted average prices of $12.9163 and $12.5508 per share, respectively. These sales were made to cover tax withholding obligations from Restricted Stock Unit (RSU) settlements, as part of a pre-approved sell-to-cover requirement, and were not discretionary. After these transactions, Fisher still holds 50,633 shares and RSUs, including 41,134 previously reported RSUs.
Responsive Playbooks and the OFIX Inflection
This article provides an in-depth analysis of Orthofix Medical Inc. (NASDAQ: OFIX), highlighting weak near and mid-term sentiment, although the long-term outlook is neutral. It identifies multiple trading strategies—position trading, momentum breakout, and risk hedging—based on AI models. The analysis also details support, resistance, and risk-reward setups for different time horizons.
A Glimpse Into The Expert Outlook On Orthofix Medical Through 5 Analysts
Five analysts have recently provided their outlook on Orthofix Medical (NASDAQ: OFIX), resulting in an average 12-month price target of $17.4, a 15.12% decrease from the previous average. The ratings show a mix of bullish and somewhat bullish sentiments, with notable adjustments in price targets from Stifel, Canaccord Genuity, and Barrington Research. The article also provides a financial overview of Orthofix Medical, highlighting its market capitalization, revenue growth, net margin, and debt management.
Orthofix Medical (OFIX) exec sells shares for RSU tax cover
Max Reinhardt, President of Global Spine at Orthofix Medical Inc. (OFIX), sold 2,133 shares of company stock on March 4 and March 5, 2026. These sales were executed solely to cover tax withholding obligations arising from restricted stock unit settlements, under a pre-approved "sell-to-cover" mandate. Following these transactions, Reinhardt directly holds 25,348 shares, which include 19,417 restricted stock units.
Orthofix Medical (NASDAQ:OFIX) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen has upgraded Orthofix Medical (NASDAQ:OFIX) stock from a "hold" to a "buy" rating, despite the broader analyst consensus remaining a "Hold" with a $18.25 price target. The medical device company recently missed quarterly EPS estimates, reporting a loss of ($0.06) against an expected $0.44, and has negative net margin and return on equity. Insiders, including the CEO and CFO, have sold shares recently, and the stock opened at $12.62 with a market capitalization of approximately $506.6 million.
Orthofix medical CP&BOO Vitale Lucas sells $29k in stock
Vitale Lucas, Chief Product and Business Operations Officer at Orthofix Medical Inc. (NASDAQ:OFIX), sold 2,312 shares of common stock for approximately $29,445 on March 4 and 5, 2026, to cover tax obligations from restricted stock units. Following these transactions, Lucas retains 164,718 shares, including restricted stock units. This news follows the company's strong Q4 2025 earnings, where EPS and revenue both exceeded analyst expectations.
Orthofix medical CLO Cedron sells $35k in OFIX stock
Orthofix Medical Inc.'s Chief Legal Officer, Jorge Andres Cedron, sold 2,775 shares of OFIX stock across two transactions on March 4 and 5, 2026, totaling $35,341. These sales were primarily to cover tax withholding obligations related to restricted stock units. Despite the sales, Orthofix recently reported a strong fourth-quarter 2025 earnings beat, exceeding analyst expectations for both EPS and revenue.
Orthofix (OFIX) grants options and RSUs to operations head
Orthofix Medical Inc.'s President of Global Operations & Quality, Aviva McPherron, received equity awards comprising 54,656 stock options and 23,024 restricted stock units on March 3, 2026. Both types of awards were granted at a price of $0.00 per share and vest in three equal annual installments over three years. Following these grants, McPherron directly holds 70,412 shares of common stock, including previously reported RSUs and shares from Orthofix's Stock Purchase Plan.
Fitbone™ Product Expansion in Limb Reconstruction
Orthofix has commercially launched the Fitbone™ Trochanteric Lengthening System in the United States, expanding its internal limb lengthening portfolio. This new system offers a trochanteric entry option, making it suitable for both adult and pediatric patients, including those with smaller anatomies. It maintains the core electromagnetic technology of Fitbone, providing a bone-conserving, minimally invasive approach for various limb reconstruction needs.
Orthofix Medical Inc. (OFIX) Target Reduced at Canaccord Following Q4 Results and 2026 Outlook Update
Canaccord has reduced its price target for Orthofix Medical Inc. (OFIX) from $24 to $20, while maintaining a Buy rating, following the company's Q4 results and updated 2026 outlook. Orthofix projects adjusted EBITDA between $95 million and $98 million and positive free cash flow for 2026. The company plans to focus on commercial execution, market penetration, and the launch of new products to drive consistent revenue growth and improve margins.
Orthofix Medical Inc. (NASDAQ:OFIX) Receives Average Recommendation of "Hold" from Brokerages
Orthofix Medical Inc. (NASDAQ:OFIX) has received an average "Hold" recommendation from six brokerages, with an average 12-month price target of $18.25. This comes after the medical device company missed Q4 earnings estimates, reporting a loss of ($0.06) versus an expected $0.44, and issued revised 2026 guidance indicating execution risk and margin delays. Despite some insider selling by the CEO and CFO, a major shareholder, Engine Capital, recently increased its stake, and institutional ownership remains high at nearly 90%.
Orthofix Medical (NASDAQ:OFIX) Shares Gap Up Following Insider Buying Activity
Orthofix Medical (NASDAQ:OFIX) shares gapped up after major shareholder Engine Capital Management significantly increased its stake by purchasing 124,797 shares at $12.55 and 13,061 shares at $12.96, raising its total holdings to approximately 3.67 million shares. This insider buying activity signals confidence despite Orthofix missing quarterly EPS expectations and management issuing revised 2026 guidance due to margin delays, which led to analyst price target cuts. The company's stock previously closed at $13.17 but opened at $13.79 on Friday following these transactions.
Orthofix Medical Inc. (OFIX) Stock Analysis: Exploring A 38.57% Upside Potential
Orthofix Medical Inc. (OFIX) is a healthcare company specializing in medical devices, particularly in spine and limb reconstruction. Analysts anticipate a 38.57% upside potential from its current trading price of $13.17, with an average target price of $18.25. Despite operational challenges like a negative EPS and ROE, the company shows modest revenue growth and positive analyst sentiment, making it a stock to watch for growth-focused investors.
Engine Capital adds to Orthofix (OFIX) stake with open-market buys
Engine Capital, through its associated entities Engine Capital, L.P. and Engine Lift Capital, LP, has increased its stake in Orthofix Medical Inc. (OFIX) by purchasing 137,858 shares in open-market transactions on February 24-25, 2026. The shares were acquired at prices ranging from $12.5455 to $12.9634 per share, making their total holdings indirectly owned. The SEC Form 4 filing also clarifies that the involved Engine Capital units and Arnaud Ajdler may be considered a Section 13(d) group beneficially owning over 10% of Orthofix common stock, though they disclaim beneficial ownership beyond their pecuniary interests.
Engine Capital Management, Lp Acquires 124,797 Shares of Orthofix Medical (NASDAQ:OFIX) Stock
Engine Capital Management, LP increased its stake in Orthofix Medical (NASDAQ:OFIX) by purchasing 124,797 shares on February 24th and an additional 13,061 shares on February 25th, bringing its total ownership to 3,663,133 shares valued at approximately $46 million. This acquisition increased their holding by 3.53%. The company recently reported an earnings miss with an EPS of -$0.06 against an expected $0.44, and analysts forecast an average "Hold" rating for the stock with a target price of $18.25.
Orthofix Medical (NASDAQ:OFIX) Major Shareholder Buys $169,270.56 in Stock
Engine Capital Management, Lp, a major shareholder in Orthofix Medical (NASDAQ:OFIX), recently increased its stake by purchasing 13,061 shares for $169,270.56 on February 25th and 124,797 shares on February 24th for approximately $1.566 million. Following these transactions, the insider now owns 3,673,092 shares valued at roughly $47.6 million. Orthofix Medical also reported its latest quarterly earnings, with an EPS of ($0.06), missing consensus estimates, but revenue slightly beat expectations, causing the stock to trade up about 1% to $13.17.
Engine capital buys Orthofix (OFIX) shares worth $1.73 million By Investing.com
Engine Capital Management, L.P. and affiliated entities, including Arnaud Ajdler, recently purchased Orthofix Medical Inc. (OFIX) shares totaling $1.73 million. These transactions, executed on February 24 and 25, 2026, occurred within a price range of $12.5455 to $12.9634 per share. Despite the stock trading down 24% over the past year, InvestingPro analysis suggests OFIX is undervalued and predicts profitability for the company this year.
Barrington Research Adjusts Orthofix Medical PT to $17 From $18, Maintains Outperform Rating
Barrington Research has adjusted its price target for Orthofix Medical (OFIX) to $17, down from $18, while maintaining an Outperform rating on the stock. This adjustment follows Orthofix Medical Inc.'s recent report of its fourth-quarter and full-year earnings results for 2025.
Orthofix Medical Inc. (NASDAQ:OFIX) Q4 2025 Earnings Call Transcript
Orthofix Medical Inc. discussed its Q4 2025 earnings, highlighting strong performance in Bone Growth Therapies and U.S. Limb Reconstruction, and double-digit net sales growth in its global Spine Fixation business. The company announced a recalibration of its 3-year financial targets, extending the timeline to 2028 to fully realize benefits from its Spine commercial channel optimization and new product launches, such as the VIRATA Spinal Fixation System. Orthofix aims for sustained top-line growth, expanding margins, and positive free cash flow, underpinned by robust commercial execution and a strong innovation pipeline.
Orthofix Medical (OFIX) Loss Narrows Sharply In Q4 Challenging Bearish Earnings Narrative
Orthofix Medical (OFIX) reported a significant narrowing of its Q4 2025 loss to US$0.06 EPS, with revenue reaching US$219.9 million, challenging a previous bearish outlook. While quarterly losses have decreased, the company remains unprofitable on a trailing 12-month basis, with analysts not forecasting profitability for the next three years. The stock trades well below its DCF fair value, creating a tension between improving quarterly results and persistent long-term unprofitability and risks.
Orthofix Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance
Orthofix Medical Inc. reported its financial results for the fourth quarter and full-year ended December 31, 2025, showing strong performance in Bone Growth Therapies and U.S. Limb Reconstruction, and double-digit year-over-year constant currency net sales growth in Global Spine Fixation. The company achieved positive free cash flow of $3.1 million for the full year 2025 and provided an optimistic financial guidance for 2026, expecting net sales between $850 million to $860 million and non-GAAP adjusted EBITDA of $95 million to $98 million. Orthofix also updated its three-year financial targets for 2026-2028, projecting above-market net sales growth, expanding profitability, and sustained positive free cash flow.
Orthofix: Q4 Earnings Snapshot
Orthofix Medical Inc. (OFIX) reported a Q4 loss of $2.2 million, or 6 cents per share, with adjusted earnings of 26 cents per share. The medical device maker posted revenues of $219.9 million for the quarter and $811.9 million for the full year, during which it reported a loss of $92.2 million, or $2.33 per share.
ORTHOFIX MEDICAL ($OFIX) Releases Q4 2025 Earnings
ORTHOFIX MEDICAL ($OFIX) reported its Q4 2025 earnings, with revenues at $218.6 million, missing estimates, but earnings per share of $0.26, beating the -$0.32 estimate. Insider trading activity showed 3 sales and no purchases in the last six months, while hedge fund activity indicated a mixed sentiment with 59 institutions adding and 111 decreasing their positions in Q4 2025. Analysts have issued "Buy" and "Outperform" ratings, with a median price target of $18.0.
Orthofix Medical Earnings Review: Q4 Summary - Orthofix Medical (NASDAQ:OFIX)
Orthofix Medical (NASDAQ: OFIX) reported its Q4 earnings, beating estimated EPS by 100.0% with an EPS of $0.24 against an estimate of $0.12. The company's revenue increased by $4.25 million compared to the same period last year. This strong performance follows a previous quarter where Orthofix Medical also exceeded EPS expectations, leading to an increase in its share price.
Orthofix Medical Inc. SEC 10-K Report
Orthofix Medical Inc. has released its 2025 10-K report, detailing financial performance, business operations, and strategic initiatives. The report highlights increased net sales and gross profit, improved operating and net losses, and the impact of its merger with SeaSpine. Despite financial improvements and strategic moves like product line discontinuation and capital management, the company faces significant challenges including integration issues, competitive pressures, supply chain disruptions, regulatory hurdles, and cybersecurity threats.
Orthofix: Fourth Quarter Financial Highlights
Orthofix Medical Inc. reported a net loss of $2.2 million, or 6 cents per share, for the fourth quarter, with adjusted earnings reaching 26 cents per share. The medical device manufacturer generated $219.9 million in revenue for the quarter. For the full fiscal year, the company posted a net loss of $92.2 million, or $2.33 per share, on total revenue of $811.9 million.
